Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 08TOKYO1782, JAPAN'S GENERIC DRUG MARKET - SMALL NOW BUT WITH

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #08TOKYO1782.
Reference ID Created Released Classification Origin
08TOKYO1782 2008-06-30 05:33 2011-08-25 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Tokyo
VZCZCXRO6044
PP RUEHFK RUEHKSO RUEHNAG RUEHNH
DE RUEHKO #1782/01 1820533
ZNR UUUUU ZZH
P 300533Z JUN 08
FM AMEMBASSY TOKYO
TO RUEHC/SECSTATE WASHDC PRIORITY 5469
INFO RUEHBJ/AMEMBASSY BEIJING PRIORITY 4152
RUEHNE/AMEMBASSY NEW DELHI PRIORITY 8545
RUEHFR/AMEMBASSY PARIS PRIORITY 6177
RUEHTV/AMEMBASSY TEL AVIV PRIORITY 0764
RUEHFK/AMCONSUL FUKUOKA PRIORITY 8639
RUEHNAG/AMCONSUL NAGOYA PRIORITY 6871
RUEHNH/AMCONSUL NAHA PRIORITY 1015
RUEHOK/AMCONSUL OSAKA KOBE PRIORITY 2368
RUEHKSO/AMCONSUL SAPPORO PRIORITY 9224
RUEHBS/USEU BRUSSELS PRIORITY
RUEHGV/USMISSION GENEVA PRIORITY 3361
RUCNDT/USMISSION USUN NEW YORK PRIORITY 0558
RUCPDOC/DEPT OF COMMERCE WASHINGTON DC PRIORITY
RUEAUSA/DEPT OF HHS WASHINGTON DC PRIORITY
UNCLAS SECTION 01 OF 03 TOKYO 001782 
 
SENSITIVE 
SIPDIS 
 
USTR FOR CUTLER, BEEMAN, HALLOWAY 
HHS FOR OHGA, STEIGER, AND BHAT 
USDOC FOR 4410/ITA/MAC/OJ/ROTH 
PARIS FOR USOECD 
 
E.O. 12958: N/A 
TAGS: ECON EINV ETRD JA PGOV SOCI
SUBJECT: JAPAN'S GENERIC DRUG MARKET - SMALL NOW BUT WITH 
HUGE POTENTIAL 
 
REF: 07 TOKYO 5080 
 
1. (SBU) Summary.  With public debt nearly double GDP and 
upward pressure on national health insurance expenditures due 
to Japan's aging society, the Ministry of Health, Labor and 
Welfare (MHLW) hopes to increase generic drugs' market share 
from 17% to 30% by 2012, saving the healthcare system an 
estimated $25 billion per year.  Consumer and physician 
resistance to generics, along with the GOJ's desire to 
protect the domestic branded pharmaceutical industry however, 
will make realizing this goal an uphill battle.  With a 
market potential of $65 billion in annual sales, foreign and 
domestic pharmaceutical manufacturers are starting to take 
notice of generics' potential in Japan, as evidenced by the 
June 15 takeover of Indian generic drugmaker Ranbaxy 
Laboratories by Japan's second largest pharmaceutical 
company, Daiichi Sankyo.  End Summary. 
 
2. (SBU) Japan's healthcare system is feeling the pressure of 
demographic and economic challenges (ref).  The country's 
society is aging rapidly with the over 65 demographic 
projected to grow from 20 percent of the population today to 
30 percent by 2025.  Moreover, the decline in overall 
population adds to the burden of those still working to 
support the growing number of seniors.  At the same time, the 
national health insurance (NHI) system encourages doctors to 
over-prescribe tests and drugs and allows hospital stays that 
are six times longer than the OECD average.  As a result, 
Japan's 2006 healthcare expenditures reached JPY32.4 trillion 
($324 billion), exceeding nine percent of national income in 
2006 for the second year in a row.  The National Federation 
of Health Insurance Societies (Kenporen), comprised of 1,502 
organizations insuring 30 million company employees and their 
dependents, projects its deficit will grow to a record 
JPY632.2 billion ($6.3 billion) in 2008. 
 
Generic Market Underdeveloped 
------------------------------ 
3. (SBU)  One factor driving spiraling healthcare costs is 
Japanese consumers' and doctors' preference for brand name 
drugs over generics.  Currently, generics have a 17% share of 
the Japanese market, compared to a 63% share in the U.S, and 
the generics market is dominated by domestic manufacturers. 
Israel's Teva Pharmaceutical, the world's leading generic 
manufacturer which holds an 11.4% share of the total U.S. 
pharmaceutical market, does virtually no business in Japan. 
 
Profits, Mistrust Dampening Adoption 
------------------------------------ 
4. (SBU) Several factors drive the preference for branded 
drugs.  The first is profit.  Many medical institutions in 
Japan dispense pharmaceuticals, earning substantial revenues 
doing so.  Even physicians in private practice often have 
profit-sharing arrangements with nearby independent "mom and 
pop" pharmacies and thus are reluctant to substitute generics 
for the more lucrative brand name drug.  The four drug 
wholesalers that dominate Japan's distribution system refuse 
to stock many generics for the same profit reasons. 
Consequently, medical institutions or pharmacies that would 
like to offer generics are often unclear as to where to 
source the drugs. 
 
5. (SBU) The second factor is the Japanese generic 
manufacturers themselves.  Most are small, unsophisticated 
companies with poor inventory management systems that produce 
frequent stock outages.  Doctors and pharmacists hesitate to 
prescribe generics for fear the product will not be 
available.  The third factor is Japanese consumers' 
skepticism of the quality and efficacy of generic drugs 
versus their branded counterparts.  Finally, MHLW regulations 
mandate a "floor" for generic drug prices so that generics 
 
TOKYO 00001782  002 OF 003 
 
 
can only be priced at a 30% discount to branded products.  As 
a result, the "co-pay" differential is minimal causing most 
consumers to stick with their trusted brand. 
 
MHLW's Five-year Plan 
--------------------- 
6. (SBU)  Nonetheless, the GOJ recognizes the need to 
encourage adoption of generics in the face of spiraling 
healthcare costs.  The MHLW has developed a five-year plan to 
increase generics' market share to 30% by 2012 which, by some 
estimates, could save the national healthcare system as much 
as $25 billion per year.  The plan seeks to address many of 
the concerns outlined above.  It requires generic 
manufacturers to eliminate in-house stock outages by 2009 so 
that all prescriptions can be promptly filled.  It mandates 
quality testing of each batch of drugs produced and compels 
manufacturers to make the information available upon request, 
both over the Internet and through brochures distributed to 
doctors and pharmacists. 
 
7. (SBU) The MHLW has also implemented changes affecting how 
generics are prescribed and how those prescriptions are 
filled.  The Ministry changed the format of doctors' 
prescription pads in April 2008 so the doctor must check a 
box specifying the patient may only be given branded product. 
 If the box is not checked, the pharmacist may give the 
consumer the option of generic or branded medications.  In 
addition, MHLW instituted a system in which pharmacists are 
awarded points based on the percentage of prescriptions they 
fill using generics.  The more points earned, the higher the 
reimbursement.  The Ministry also issued guidelines to 
doctors and hospitals "encouraging" them to promote the use 
of generics or risk losing insurance reimbursements. Finally, 
MHLW issued an ordinance requiring all prescriptions for 
welfare recipients be filled with generic drugs. 
 
A $65 billion market? 
--------------------- 
8. (SBU) Still, many feel the GOJ's efforts fall short. 
Despite the healthcare system's perilous fiscal situation, 
MHLW wants to proceed cautiously in promoting generics, 
according to Hiroshi Mitsuhara, President and CEO of Nihon 
Chouzai Company, one of Japan's largest drugstore chains. 
The Ministry fears more aggressive measures may imperil 
domestic branded pharmaceutical manufacturers, he said. 
Regardless of MHLW's and the Japanese public's reticence, 
generics will inevitably play an increasingly important role 
in the Japanese healthcare system and could eventually top 
JPY7 trillion ($65 billion) in sales per year, Mitsuhara 
predicted.  He noted Nihon Chouzai currently stocks over 500 
generic products, more than twice the average of other 
drugstores. 
 
Daiichi Sankyo Buys India's Ranbaxy 
----------------------------------- 
9. (SBU) Recognizing this market potential, Daiichi Sankyo, 
Japan's second largest pharmaceutical manufacturer, announced 
the purchase of India's Ranbaxy Laboratories June 15.  The 
eighth largest pharmaceutical company in the world, Ranbaxy 
has annual gross sales of JPY180 billion ($1.7 billion) and 
operates in 49 countries, according to Japanese press 
reports.  Ranbaxy entered the Japanese market in 2002, 
forming a joint venture with Japanese generic manufacturer 
Nippon Chemiphai.  The company's strategic advantage lies in 
its ability to use India's low-cost manufacturing base to 
generate higher profits than its competitors who produce in 
Japan, according to Satyesh Varhadkar, Ranbaxy's head 
representative in Japan. The joint venture currently has four 
products that have been approved by the pharmaceutical and 
medical devices agency and are currently in market, Varhadkar 
stated.  Nevertheless, Varhadkar believes it will be many 
 
TOKYO 00001782  003 OF 003 
 
 
years before generics command a substantial Japanese market 
share.  He lamented the difficulty his and other foreign 
firms face competing in the Japanese pharmaceutical market 
and suggested the only way to overcome the significant 
consumer and structural barriers is to form a joint venture 
with a domestic entity. 
 
Comment 
------- 
10. (SBU) Persuading brand-obsessed Japanese consumers who 
will queue up for hours to get the "real thing", whether it 
be Gucci handbags or Krispy Kreme doughnuts, to switch to 
generic drugs will likely be an uphill battle.  With public 
debt running about double GDP and upward pressure on medical 
expenditures due to an aging society, however, the GOJ may be 
forced to take more aggressive steps to push the use of 
generics.  The MHLW goal to raise generics' share to 30% in 
the world's second largest pharmaceutical market could be a 
huge opportunity for U.S. and other generic manufacturers 
willing to take on the coterie of vested interests that 
control the prescription drug market in Japan.  End comment. 
 
SCHIEFFER